Biotech startup Enveda is using artificial intelligence to search thousands of plants for potential drug breakthroughs. The Colorado-based company recently achieved unicorn status with a $150 million funding round, valuing it at over $1 billion. Enveda’s approach combines traditional plant-based medicine knowledge with AI to identify promising molecules for drug development. The firm has already begun its first clinical trial and plans to expand its pipeline. This innovative method aims to accelerate the discovery of new medicines from natural sources.